The US Federal Trade Commission has voted 4-0 approving a final order to settle charges that ANI Pharmaceuticals’ $210m acquisition of Novitium Pharma violated federal antitrust laws, following a public comment period.
In November last year, the FTC told ANI it must divest development rights for one generic drug and assets belonging to another to authorized generics specialist Prasco, in order to close
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?